Table 8.
Risk for neoplasia at 2nd surveillance stratified by findings at baseline and 1st surveillance
| Baseline Finding | 1st Surveillance Finding | High Risk Adenoma at 2nd Surveillance, % | |||||
|---|---|---|---|---|---|---|---|
| Morelli M 2013 (n=965)38 | Park HW 2015 (n=2087)39 | van Heijningen EB 2013 (n=1482)*22 | Pinsky P 2009 (n=1032)*43 | Laiyemo A 2009 (n=1297)44 | Robertson D 2009 (n=564)45 | ||
| Low risk adenoma (LRA) | No adenoma | 6.6 | 6.0 | 1.0 | 3.9 | 2.8 | 4.9 |
| LRA | 13.8 | 10.6 | 1.0 | 5.7 | 4.7 | 9.5 | |
| HRA | 18.0 | 16.4 | 0.0 | 15.6 | 6.9 | 20.0 | |
| High risk adenoma (HRA) | No adenoma | 9.6 | 6.7 | 4.0 | 5.9 | 4.8 | 12.3 |
| LRA | 14.0 | 24.3 | 3.0 | 6.7 | 8.9 | 13.6 | |
| HRA | 22.0 | 38.2 | 4.0 | 19.3 | 30.6 | 18.2 | |
LRA=1–2 non-advanced adenomas; HRA=advanced adenoma or ≥ 3 adenomas
*
risk and outcome characterized based on non-advanced and advanced adenoma